PASCAL implant
Designed to reduce leaflet stress and increase open orifice area enabling low gradients
Meet the PASCAL
Precision System
The latest advancement from Edwards Lifesciences in transcatheter mitral therapies: The PASCAL Precision system
Discover the difference with the PASCAL implants
Designed for patient-focused care
PASCAL Ace implant
Features a narrower design profile to help you optimize your treatment of degenerative mitral regurgitation
The PASCAL Ace and PASCAL implants offer different designs with the same functionality.
Features
Treat your patients with degenerative mitral regurgitation with the latest transcatheter mitral innovation from Edwards Lifesciences
Versatile implant configuration to navigate even challenging anatomies
Adapt to specific procedural and anatomical needs
A wide range of paddle mobility and full elongation capabilities helps you maneuver, reconfigure, and retrieve the implant prior to release
Overview of the PASCAL Precision system
Advanced catheter technologies facilitate smooth navigation and implant deployment
Watch the PASCAL Precision system in action
Clinical evidence
CLASP IID: The first randomized controlled trial to directly compare two contemporary TEER therapies
CLASP: An international, multi-center prospective safety and clinical outcomes study
CLASP IID trial
The objective of this prospective, multicenter, randomized, controlled pivotal trial is to evaluate safety and effectiveness in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team.
1 / 5
MR Reduction
All-cause mortality
Heart failure hospitalization
New York Heart Association Functional Class
KCCQ Score
2. Zahr F, Smith RL, Gillam LD, et.al. One-year Outcomes from the CLASP IID Randomized Trial for Degenerative Mitral Regurgitation. J Am Coll Cardiol Intv 2023; Oct 26; [Epub Ahead of Print]; DOI: https://doi.org/10.1016/j.jcin.2023.10.002
CLASP IID is a clinical trial from Edwards Lifesciences, reinforcing TEER as safe and effective for the treatment of patients with degenerative mitral regurgitation.
CLASP trial
Demonstrated sustained MR reduction and functional improvement at 2 years3*
1 / 4
DMR
Survival
Freedom from HF rehospitalization
New York Heart Association Functional Class
3. Szerlip M, Spargias KS, Makkar R, Kar S, Kipperman RM, O’Neill WW, et al. 2-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. JACC Cardiovasc Interv. 2021 Jul 26;14:1538-1548. Epub 2021 May 18. Erratum in JACC Cardiovasc Interv. 2022 Jul 11;15:1395.